Chemical Structure (Alogliptin 01)
Alogliptin Tablet, Film Coated
Product Images NDC 45802-103
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Alogliptin (NDC 45802-103). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Padagis Israel Pharmaceuticals Ltd, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Alogliptin 02)
This appears to be a chart or table with information about the drug Alogliptin and its interaction with other drugs. It includes dosing recommendations and information about how Alogliptin is processed by the body.*
Figure 2 (Alogliptin 03)
This is a list of drugs that have been co-administered along with their doses and frequency. The text mentions whether the drug is renally excreted or inhibits certain enzymes or proteins. The list recommends no dose adjustment for any of the drugs.*
Figure 3 (Alogliptin 04)
The text seems to be a table with measurements of mean A1C and LS Mean Change in A1C (%) for different dosages of placebo, alogliptin, pioglitazone, and their combination. There are some statistically significant differences between the combination therapy and alogliptin or pioglitazone used alone. The population analyzed was intent-to-treat, and the last observation on the study was used.*
Figure 4 (Alogliptin 05)
The text seems to be part of a study or research as it includes details related to comparing the effects of the drug NESINA versus Placebo (P). It highlights the results of the study by showing the HR (hazard ratio) for NESINA versus Placebo. The data also includes the number of participants in each group (N and P) and the number of months from randomization. However, due to the lack of context and missing information, it is difficult to provide a more specific description of the study.*
Principal Display Panel (6.25 mg Tablet Bottle Label)
This is a medication package containing film-coated tablets of Alogliptin, benzolate equivalent to 6.25mg of Alogliptin used for glycemic control for people with type 2 diabetes. The package insert is recommended to determine usage, and it should be kept at a controlled room temperature between 15-30°C (59°-86°F). The seal over the bottle should not be accepted if broken or missing, and the medicine should be kept away from the reach of children. This package contains 30 tablets and should be dispensed with a medication guide. Distributed by Perrigo, Allegan, MI 4010.*
Principal Display Panel (12.5 mg Tablet Bottle Label)
This is a medication warning label for Alogliptin tablets of 12.5mg containing Alogliptin benzoate, distributed by Perrigo. The label advises to not accept broken bottle seals, to keep out of reach of children and lists the usual dosage. The tablets are film-coated and must be stored at 25°C with excursions allowed between 15°-30°C. The label has a reference number, batch code and a National Drug Code. Patients receiving the medication should also receive a Medication Guide with the product.*
Principal Display Panel (25 mg Tablet Bottle Label)
This text contains information about a medication called Alogliptin. The packaging advises not to accept if the seal is broken or missing, and to keep it out of reach of children. It provides details such as the dosage, storage instructions, the ingredients and the manufacturer. It also mentions that each film-coated tablet contains 34mg of Alogliptin benzoate equivalent to 25mg of Alogliptin. Finally, it states that it comes with a Medication Guide and is dispensed with 30 tablets.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
